notoginsenoside Ft1: stimulates angiogenesis; isolated from Panax notoginseng; structure in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
| Flora | Rank | Flora Definition | Family | Family Definition |
|---|---|---|---|---|
| Panax | genus | An araliaceous genus of plants that contains a number of pharmacologically active agents used as stimulants, sedatives, and tonics, especially in traditional medicine. Sometimes confused with Siberian ginseng (ELEUTHEROCOCCUS).[MeSH] | Araliaceae | The ginseng plant family of the order Apiales, subclass Rosidae, class Magnoliopsida. Leaves are generally alternate, large, and compound. Flowers are five-parted and arranged in compound flat-topped umbels. The fruit is a berry or (rarely) a drupe (a one-seeded fruit). It is well known for plant preparations used as adaptogens (immune support and anti-fatigue).[MeSH] |
| ID Source | ID |
|---|---|
| PubMed CID | 91973814 |
| MeSH ID | M0578235 |
| Synonym |
|---|
| 155683-00-4 |
| notoginsenoside ft1 |
| HY-N0910 |
| mfcd22125013 |
| AKOS037515008 |
| beta-d-glucopyranoside, (3beta,12beta,20r)-12,20-dihydroxydammar-24-en-3-yl o-beta-d-xylopyranosyl-(1-->2)-o-beta-d-glucopyranosyl-(1-->2)- |
| MS-31713 |
Notoginsenoside Ft1 (Ft1) is a bioactive saponin from the leaves of P. notoginseng. It is used traditionally for the treatment of trauma injuries in East Asia.
| Excerpt | Reference | Relevance |
|---|---|---|
| "Notoginsenoside Ft1 (Ft1) is a bioactive saponin from the leaves of P." | ( Notoginsenoside Ft1 activates both glucocorticoid and estrogen receptors to induce endothelium-dependent, nitric oxide-mediated relaxations in rat mesenteric arteries. Hou, M; Huang, Y; Ji, L; Leung, SW; Shen, K; Vanhoutte, PM; Wang, Z; Xu, A, 2014) | 2.57 |
| "Notoginsenoside Ft1 (Ft1) is a saponin isolated from Panax notoginseng, which has been used traditionally for the treatment of trauma injuries in East Asia. " | ( Notoginsenoside Ft1 promotes angiogenesis via HIF-1α mediated VEGF secretion and the regulation of PI3K/AKT and Raf/MEK/ERK signaling pathways. Fan, Y; Gong, C; Hou, M; Ji, L; Ma, Y; Shen, K; Wang, Z; Yang, L, 2012) | 3.26 |
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 6 (85.71) | 24.3611 |
| 2020's | 1 (14.29) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.
| This Compound (12.48) All Compounds (24.57) |
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 0 (0.00%) | 5.53% |
| Reviews | 0 (0.00%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 7 (100.00%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||